1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.
Overview
- Department of Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy; (M.R.); (S.Q.); (A.B.); (M.D.P.); (P.P.)
- Department of Women’s and Children’s Health, University of Padova, Via Giustiniani, 3, 35128 Padova, Italy
- Pediatric Research Institute–IRP, Corso Stati Uniti 4, 35127 Padova, Italy
- Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell’Università 16, 35020 Legnaro, Italy; (L.L.); (V.D.P.); (F.C.)
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy; (R.L.)
- Laboratory of Drug Metabolism, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo Egidio Meneghetti 2, 35131 Padova, Italy
Abstract
Glioblastoma multiforme is the most aggressive primary brain tumor in adults, which displays extremely poor prognosis. Protease-activated receptor 2 (PAR2) and its downstream effector SerpinB3 are overexpressed in aggressive glioblastomas. In this study we evaluated the antitumor activity of 1-piperidine propionic acid (1-PPA), an allosteric PAR2 inhibitor, in in vitro preclinical models of glioblastoma. PAR2 and SerpinB3 were analyzed at the transcriptional and protein level in glioblastoma cell lines and primary cultures. These were treated with 1-PPA alone or in association with temozolomide (TMZ) and the effects evaluated by Incucyte® technology. Pharmacokinetics and tissue distribution of 1-PPA were assessed in mice by LC-MS/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE7696 — at NCBI GEO; found in the text, “4.8. Statistical Analysis”
Data Availability Statement
Glioblastoma patient data, including the TCGA, CGGA, Murat (GSE7696 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 13 authors, 5 keywords, 15 MeSH terms, 2 funders, 69 references.
Cite
This paper
Ruvoletto, M., Quarta, S., Rampazzo, E., Lucatello, L., Luisetto, R., Villano, G., Di Paolo, V., Biasiolo, A., Di Pascoli, M., Quintieri, L., Capolongo, F., Persano, L., & Pontisso, P. (2026). 1-Piperidine Propionic Acid Inhibits PAR2/
BibTeX
@article{ruvoletto20261,
author = {Ruvoletto, Mariagrazia and Quarta, Santina and Rampazzo, Elena and Lucatello, Lorena and Luisetto, Roberto and Villano, Gianmarco and Di Paolo, Veronica and Biasiolo, Alessandra and Di Pascoli, Marco and Quintieri, Luigi and Capolongo, Francesca and Persano, Luca and Pontisso, Patrizia},
title = {{1-Piperidine Propionic Acid Inhibits PAR2/
journal = {International journal of molecular sciences},
year = {2026},
month = aug,
volume = {27},
number = {16},
pages = {7240},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {1422-0067},
doi = {10.3390/
url = {https://
pmid = {42653244},
pmcid = {PMC13513849}
}
RIS
TY - JOUR
AU - Ruvoletto, Mariagrazia
AU - Quarta, Santina
AU - Rampazzo, Elena
AU - Lucatello, Lorena
AU - Luisetto, Roberto
AU - Villano, Gianmarco
AU - Di Paolo, Veronica
AU - Biasiolo, Alessandra
AU - Di Pascoli, Marco
AU - Quintieri, Luigi
AU - Capolongo, Francesca
AU - Persano, Luca
AU - Pontisso, Patrizia
TI - 1-Piperidine Propionic Acid Inhibits PAR2/
T2 - International journal of molecular sciences
J2 - Int J Mol Sci
PY - 2026
DA - 2026/
VL - 27
IS - 16
SP - 7240
SN - 1422-0067
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3390/
"type": "article-journal",
"title": "1-Piperidine Propionic Acid Inhibits PAR2/
"container-title": "International journal of molecular sciences",
"author": [
{
"family": "Ruvoletto",
"given": "Mariagrazia"
},
{
"family": "Quarta",
"given": "Santina"
},
{
"family": "Rampazzo",
"given": "Elena"
},
{
"family": "Lucatello",
"given": "Lorena"
},
{
"family": "Luisetto",
"given": "Roberto"
},
{
"family": "Villano",
"given": "Gianmarco"
},
{
"family": "Di Paolo",
"given": "Veronica"
},
{
"family": "Biasiolo",
"given": "Alessandra"
},
{
"family": "Di Pascoli",
"given": "Marco"
},
{
"family": "Quintieri",
"given": "Luigi"
},
{
"family": "Capolongo",
"given": "Francesca"
},
{
"family": "Persano",
"given": "Luca"
},
{
"family": "Pontisso",
"given": "Patrizia"
}
],
"container-title-short":
"volume": "27",
"issue": "16",
"page": "7240",
"DOI": "10.3390/
"PMID": "42653244",
"PMCID": "PMC13513849",
"ISSN": "1422-0067",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
13
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.32604/or.2026.079221
- Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.Journal: Oncology researchIn common: other condition, mouse, cellular / molecular, 6 references
- [2] doi:10.1186/s40478-026-02318-7
- Glioblastoma cells utilize evolutionarily adapted cell metabolism to promote their malignant proliferation.Journal: Acta neuropathologica communicationsIn common: other condition, cellular / molecular, 5 references
- [3] doi:10.1038/s41467-026-74058-0
- IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2.Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, 4 references
- [4] doi:10.1080/17501911.2026.2691031
- Promoter methylation-associated brain-enriched long noncoding RNAs in glioblastoma: a multi-cohort public epigenomic re-analysis.Journal: EpigenomicsIn common: other condition, cellular / molecular, 5 references
- [5] doi:10.3390/cancers18132092
- TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
ed Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study. Journal: CancersIn common: other condition, 5 references - [6] doi:10.1158/2767-9764.crc-25-0579 [code]
- Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses.Journal: Cancer research communicationsIn common: other condition, mouse, 4 references
- [7] doi:10.1186/s12967-026-08266-z [code]
- Single-cell multi-omic integration analysis prioritizes druggable genes and reveals cell-type-specific causal effects in glioblastomagenesis.Journal: Journal of translational medicineIn common: other condition, cellular / molecular, 4 references
- [8] doi:10.1126/sciadv.adz5324 [code]
- High mannose content of mesenchymal glioblastoma correlates with hydroxyl proton transfer-weighted (HPTw) MRI as noninvasive biomarker of tumor aggressiveness.Journal: Science advancesIn common: other condition, 4 references
- [9] doi:10.3390/ijms27136068 [code]
- Loss of Neuropeptide Y Signaling Accompanies the Neural-to-Mesenchymal Transcriptional Transition in Glioblastoma: A Multi-Scale Transcriptomic Analysis.Journal: International journal of molecular sciencesIn common: other condition, cellular / molecular, 4 references
- [10] doi:10.1039/d5dd00190k [code]
- Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.Journal: Digital discoveryIn common: other condition, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.